eMedicine Specialties > Pulmonology > Altitude Edema and Lung Diseases

Pulmonary Edema, High-Altitude

Author: Rohit Goyal, MD, Fellow, Division of Pulmonary Medicine, Lenox Hill Hospital, New York University School of Medicine
Coauthor(s): Mir Omar Ali, MD, Fellow, Department of Pulmonary Medicine, Lenox Hill Hospital, New York University; Samia Qazi, MD, Director of the Travel and Immunization Clinic, Nassau County Medical Center; Assistant Professor, Department of Internal Medicine, State University of New York Health Science Center at Stony Brook; Laurie Ward, MD, Chief, Co-Director of Travel and Immunization Clinic, Nassau County Medical Center; Assistant Professor, Department of Internal Medicine, Division of Primary Care, State University of New York at Stony Brook; Qazi Qaisar Afzal, MD, Clinical Instructor, Department of Medicine, State University of New York at Stony Brook; Mir Mustafa Ali, Deccan College of Medical Sciences, Owaisi Hospital and Research Center, Princess Esra Hospital, India; Klaus-Dieter Lessnau, MD, FCCP, Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital
Contributor Information and Disclosures

Updated: Sep 17, 2009

Introduction

Background

High-altitude illness may result from short-term exposures to altitudes in excess of 2000 m (6560 ft). This illness comprises a spectrum of clinical entities that are probably the manifestations of the same disease process. High-altitude pulmonary edema (HAPE) and cerebral edema are the most ominous of these symptoms, while acute mountain sickness, retinal hemorrhages, and peripheral edema are the milder forms of the disease. The rate of ascent, the altitude attained, the amount of physical activity at high altitude, and individual susceptibility are contributing factors to the incidence and severity of high-altitude illness.

Also see Altitude Illness, Cerebral Syndromes and Altitude Illness, Pulmonary Syndromes.

Pathophysiology

The pathophysiology high-altitude pulmonary edema (HAPE) is not well understood. HAPE is a noncardiogenic form of pulmonary edema resulting from a leak in the alveolar capillary membrane. The various mechanisms believed to be responsible are pulmonary arterial vasoconstriction resulting in circulatory shear forces and a consequent permeability leak and antidiuresis possibly mediated by increased antidiuretic hormones, which contribute to fluid retention. The inciting factor appears to be excessive hypoxia.

A number of compensatory mechanisms improve oxygen delivery when its inspired concentration is reduced. The first adaptation to high altitude is an increase in minute ventilation. The ventilatory response to a relatively hypoxic stimulus can be divided into 4 phases: (1) initial increase on ascent, (2) subsequent course over hours and weeks, (3) deacclimatization on descent, and (4) long-term response of high-altitude natives.

The barometric pressure decreases with distance above the Earth's surface in an approximately exponential manner. The pressure at 5500 m (18,000 ft) is only half the normal 760 mm Hg, so that the partial pressure of oxygen (PO₂) of moist inspired gas is (380-47) X 0.2093 = 70 (47 mm Hg is the partial pressure of water vapor at body temperature [ie, 37ºC]). At the summit of Mount Everest (altitude 8848 m or 29,028 ft), the inspired PO₂ is only 43. In spite of hypoxia associated with high altitude, approximately 15 million people live at elevations over 3050 m, and some permanent residents live higher than 4900 m in the Andes. A remarkable degree of acclimatization occurs when humans ascend to these altitudes. Climbers have lived for several days at altitudes that would cause unconsciousness within a few seconds in the absence of acclimatization.

Spirometric studies have shown that with increasing altitude, both forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁) are reduced by up to 25% (74.8% / 74.6% of baseline). In the same study, peak expiratory flow (PEF) initially increased up to 4451 m and returned to baseline values above 5000 m. After descent below 2000 m, all values normalized within one day. These findings were consistent with increasing pulmonary restriction at high altitudes (without a marked reduction of PEF). Portable spirometry may provide clinically relevant information (impending pulmonary edema) in high-altitude travelers.¹

Bronchoalveolar lavage fluid (BALF) studies have shown that after heavy exercise, under all conditions, athletes develop a permeability edema with high BALF RBC and protein concentrations in the absence of inflammation. Exercise at altitude (3810 m) caused significantly greater leakage of RBCs (92,000 [SD 3.1] cells/mL) into the alveolar space than that seen with normoxic exercise (54,000 [SD 1.2] cells/mL). At altitude, the 26-hour postexercise BALF had significantly higher RBC and protein concentrations, suggesting an ongoing capillary leak. These findings suggest that pulmonary capillary disruption occurs with intense exercise in healthy humans and that hypoxia augments the mechanical stresses on the pulmonary microcirculation.²

Autopsy studies performed on patients who died of HAPE have shown a proteinaceous exudate with hyaline membranes. The studies have shown areas of pneumonitis with neutrophil accumulation, although none was noted to contain bacteria. Pulmonary veins were not dilated. Most reports mention capillary and arteriolar thrombi with deposits of fibrin, hemorrhage, and infarcts. The findings suggest a protein-rich edema with a possibility that clotting abnormalities may be partially responsible for this illness.

Bronchoalveolar lavages performed on patients with HAPE have also shown the fluid to have a high protein content, higher than in patients with adult respiratory distress syndrome (ARDS). The fluid was also highly cellular. Unlike ARDS, which primarily has neutrophils in the lavage fluid, HAPE fluid contains a higher percentage of alveolar macrophages. Additionally, chemotactic (leukotriene B4) and vasoactive (thromboxane B2) mediators were present in the lavage.

Frequency

United States

In one study on Colorado skiers, the incidence of acute mountain sickness was as high as 15-40%. The incidence of high-altitude pulmonary edema (HAPE) is much lower, at about 0.1-1%.

International

In a study on Mount Everest trekkers, the incidence of high-altitude pulmonary edema (HAPE) was about 1.6%. The incidence of mountain sickness appears to be unusually high in trekkers on Mount Rainier; however, the incidence of pulmonary edema is the same as in other places. One study reported that Everest region trekkers were more likely to be evacuated for altitude illness than trekkers in other regions.³

Mortality/Morbidity

High-altitude pulmonary edema (HAPE) may be fatal within a few hours if left untreated. Patients who recover from HAPE have rapid clearing of edema fluid and do not develop long-term complications. One study has shown that the estimated incidence of altitude illness–related death was 7.7 deaths in 100,000 trekkers. The mortality has been increasing over the last decade.³

Sex

Men and women are equally susceptible to acute mountain sickness, but women may be less likely to develop high-altitude pulmonary edema (HAPE). In addition to individual differences in susceptibility, other factors, such as alcohol, respiratory depressants, and respiratory infections, may enhance vulnerability to altitude illness.

Age

The typical patient with high-altitude pulmonary edema (HAPE) is a young person who is otherwise physically fit. HAPE is rare in infants and small children.

Clinical

History

• High-altitude pulmonary edema (HAPE) generally occurs 1-4 days after rapid ascent to altitudes in excess of 2500 m (8000 ft). Young people and previously acclimatized people reascending to a high altitude following a short stay at low altitude seem more predisposed to HAPE. Cold weather and physical exertion at high altitude are other predisposing factors.
• The earliest indications are decreased exercise tolerance and slow recovery from exercise.
• The person usually notices fatigue, weakness, and dyspnea on exertion.
• The condition typically worsens at night, and tachycardia and tachypnea occur at rest. Periodic breathing during sleep is almost universal in sojourners at high altitude.
• Cough, frothy sputum, cyanosis, rales, and dyspnea progressing to severe respiratory distress are symptoms of the disease.
• A low-grade fever, respiratory alkalosis, and leukocytosis are other common features.
• In severe cases, an altered mental status, hypotension, and death may result.

Physical

In addition to the symptoms discussed, high-altitude pulmonary edema (HAPE) is diagnosed by the presence of at least 2 of the following signs:

• Tachycardia
• Tachypnea
• Crackles on auscultation
• Central cyanosis
• Disproportionately low oxygen saturation relative to altitude

Causes

• Rapid ascent
• Physical exertion at high altitude
• Exposure to cold

• Search for CME/CE on This Topic »

• High-Altitude Cardiopulmonary Diseases (Pediatrics: General Medicine)
• Congestive Heart Failure and Pulmonary Edema (Emergency Medicine)
• Pulmonary Edema, Noncardiogenic (Radiology)
• Pulmonary Hypertension, High Altitude (Pediatrics: Cardiac Disease and Critical Care Medicine)

• Mountain Sickness Symptoms
• Mountain Sickness Overview
• Environmental Exposures and Injuries
• Mountain Sickness Causes
• Mountain Sickness Treatment

• High-Altitude Mountain Climbing Linked With Corneal Swelling
• Carb Intake Does Not Curb High Altitude Muscle Loss
• Hopes Build for Natriuretic-Peptide Risk Stratification Before Noncardiac Surgery

• Altitude and the Heart: Is Going High Safe for Your Cardiac Patient?
• Furosemide: A Review of its Use in Infants and Children
• Pulmonary Actinomycosis Presenting as a Mass-like Consolidation